Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia
Recently, immunotherapies with allogeneic dendritic cells (DCs) pulsed with tumor antigens to generate specific T-cell responses have been tested in clinical trials for patients with solid tumors. This is the first report on a clinical vaccination study with DCs for patients with B-cell chronic lymp...
Gespeichert in:
| Veröffentlicht in: | Leukemia 2005-09, Vol.19 (9), p.1621-1627 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1627 |
|---|---|
| container_issue | 9 |
| container_start_page | 1621 |
| container_title | Leukemia |
| container_volume | 19 |
| creator | HUS, I ROLINSKI, J TABARKIEWICZ, J WOJAS, K BOJARSKA-JUNAK, A GREINER, J GIANNOPOULOS, K DMOSZYNSKA, A SCHMITT, M |
| description | Recently, immunotherapies with allogeneic dendritic cells (DCs) pulsed with tumor antigens to generate specific T-cell responses have been tested in clinical trials for patients with solid tumors. This is the first report on a clinical vaccination study with DCs for patients with B-cell chronic lymphocytic leukemia (B-CLL). The potential of allogeneic DCs pulsed ex vivo with tumor cell lysates or apoptotic bodies to stimulate antitumor immunity in patients with B-CLL in early stages was evaluated. Monocyte-derived DCs were obtained from unrelated healthy donors. Nine patients (clinical stage 0 and 1 according to Rai) were vaccinated five times with a mean number of 32 x 10(6) stimulated DCs administered intradermally once every 2-3 weeks. No signs of autoimmunity were detected, and only mild local skin reactions were noted. During the treatment period, we observed a decrease of peripheral blood leukocytes and CD19+/CD5+ leukemic cells. In one patient, a significant increase of specific cytotoxic T lymphocytes against RHAMM/CD168, a recently characterized leukemia-associated antigen, could be detected after DC vaccination. Taken together, the study demonstrated that DC vaccination in CLL patients is feasible and safe. Immunological and to some extent hematological responses could be noted, justifying further investigation on this immuno-therapeutical approach. |
| doi_str_mv | 10.1038/sj.leu.2403860 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68515234</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A188525041</galeid><sourcerecordid>A188525041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c569t-522feac625771df3e77cba8b9f1b749427e2986f46769418f4e5a1dfb0617a303</originalsourceid><addsrcrecordid>eNqFkk2P1DAMhisEYoeFKzdQBWJvHZI0H-1xWPElrcQFzlWautMMaVKSVKv-Fv4sqWZgAC1COcRxHr-2E2fZU4y2GJXV63DYGpi3hKYDR_eyDaaCF4wxfD_boKoSBa8JvcgehXBAaL3kD7MLzOoaVRxvsu87Y9weLGiVd2A7r2OyFBgT8mk2Abr8Vschj_PofG6WICOEPJlyclN0K9y6TiefDLkex9m6OICX05L3iZpk1GBjOIqA9GYpQpR7yN8Ua5JcDd7ZJGKWcRqcWlbB1NBXGLV8nD3oZSrhyWm_zL68e_v5-kNx8-n9x-vdTaEYr2PBCOlBKk6YELjrSxBCtbJq6x63gtaUCCB1xXvKBa8prnoKTCawRRwLWaLyMrs66k7efZshxGbUYa1OWnBzaHjFMCMl_S-IRVlRjFbFl3-BBzd7m5poCKdMIIFYmagX_6RIAnBJ8FlqLw002vYueqnWvM0OVxUjDNGV2t5BpdWlh1TOQq-T_4-Aq98CBpAmDsGZOWpnw53KyrsQPPTN5PUo_dJg1Kwj2IRDk36sOY1gCnh-6mpuR-jO-GnmEvDqBMigpOm9tEqHMydQLVL6xD07clbG2cMv4GeiH_cM7hw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220531321</pqid></control><display><type>article</type><title>Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>HUS, I ; ROLINSKI, J ; TABARKIEWICZ, J ; WOJAS, K ; BOJARSKA-JUNAK, A ; GREINER, J ; GIANNOPOULOS, K ; DMOSZYNSKA, A ; SCHMITT, M</creator><creatorcontrib>HUS, I ; ROLINSKI, J ; TABARKIEWICZ, J ; WOJAS, K ; BOJARSKA-JUNAK, A ; GREINER, J ; GIANNOPOULOS, K ; DMOSZYNSKA, A ; SCHMITT, M</creatorcontrib><description>Recently, immunotherapies with allogeneic dendritic cells (DCs) pulsed with tumor antigens to generate specific T-cell responses have been tested in clinical trials for patients with solid tumors. This is the first report on a clinical vaccination study with DCs for patients with B-cell chronic lymphocytic leukemia (B-CLL). The potential of allogeneic DCs pulsed ex vivo with tumor cell lysates or apoptotic bodies to stimulate antitumor immunity in patients with B-CLL in early stages was evaluated. Monocyte-derived DCs were obtained from unrelated healthy donors. Nine patients (clinical stage 0 and 1 according to Rai) were vaccinated five times with a mean number of 32 x 10(6) stimulated DCs administered intradermally once every 2-3 weeks. No signs of autoimmunity were detected, and only mild local skin reactions were noted. During the treatment period, we observed a decrease of peripheral blood leukocytes and CD19+/CD5+ leukemic cells. In one patient, a significant increase of specific cytotoxic T lymphocytes against RHAMM/CD168, a recently characterized leukemia-associated antigen, could be detected after DC vaccination. Taken together, the study demonstrated that DC vaccination in CLL patients is feasible and safe. Immunological and to some extent hematological responses could be noted, justifying further investigation on this immuno-therapeutical approach.</description><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/sj.leu.2403860</identifier><identifier>PMID: 15990861</identifier><identifier>CODEN: LEUKED</identifier><language>eng</language><publisher>London: Nature Publishing</publisher><subject>Aged ; Antigen (leukemia-associated) ; Antigen (tumor-associated) ; Antigens ; Apoptosis ; Apoptosis - immunology ; Autoimmunity ; Biological and medical sciences ; Cancer Vaccines - therapeutic use ; CD19 antigen ; CD5 antigen ; Chronic lymphocytic leukemia ; Clinical trials ; Cytotoxicity ; Dendritic cells ; Dendritic Cells - immunology ; Extracellular Matrix Proteins - immunology ; Female ; Hematologic and hematopoietic diseases ; Humans ; Hyaluronan Receptors - immunology ; Immunology ; Immunotherapy ; Immunotherapy - methods ; Leukemia ; Leukemia, Lymphocytic, Chronic, B-Cell - immunology ; Leukemia, Lymphocytic, Chronic, B-Cell - therapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Leukocytes ; Lymphatic leukemia ; Lymphocytes ; Lymphocytes B ; Lymphocytes T ; Lysates ; Male ; Medical sciences ; Middle Aged ; Monocytes ; Neoplasm Proteins - immunology ; Patients ; Peripheral blood ; Reverse Transcriptase Polymerase Chain Reaction ; Solid tumors ; Th1 Cells - immunology ; Th2 Cells - immunology ; Treatment Outcome ; Tumors ; Vaccination ; Vaccines</subject><ispartof>Leukemia, 2005-09, Vol.19 (9), p.1621-1627</ispartof><rights>2006 INIST-CNRS</rights><rights>COPYRIGHT 2005 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Sep 2005</rights><rights>Nature Publishing Group 2005.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c569t-522feac625771df3e77cba8b9f1b749427e2986f46769418f4e5a1dfb0617a303</citedby><cites>FETCH-LOGICAL-c569t-522feac625771df3e77cba8b9f1b749427e2986f46769418f4e5a1dfb0617a303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2727,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17097885$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15990861$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HUS, I</creatorcontrib><creatorcontrib>ROLINSKI, J</creatorcontrib><creatorcontrib>TABARKIEWICZ, J</creatorcontrib><creatorcontrib>WOJAS, K</creatorcontrib><creatorcontrib>BOJARSKA-JUNAK, A</creatorcontrib><creatorcontrib>GREINER, J</creatorcontrib><creatorcontrib>GIANNOPOULOS, K</creatorcontrib><creatorcontrib>DMOSZYNSKA, A</creatorcontrib><creatorcontrib>SCHMITT, M</creatorcontrib><title>Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia</title><title>Leukemia</title><addtitle>Leukemia</addtitle><description>Recently, immunotherapies with allogeneic dendritic cells (DCs) pulsed with tumor antigens to generate specific T-cell responses have been tested in clinical trials for patients with solid tumors. This is the first report on a clinical vaccination study with DCs for patients with B-cell chronic lymphocytic leukemia (B-CLL). The potential of allogeneic DCs pulsed ex vivo with tumor cell lysates or apoptotic bodies to stimulate antitumor immunity in patients with B-CLL in early stages was evaluated. Monocyte-derived DCs were obtained from unrelated healthy donors. Nine patients (clinical stage 0 and 1 according to Rai) were vaccinated five times with a mean number of 32 x 10(6) stimulated DCs administered intradermally once every 2-3 weeks. No signs of autoimmunity were detected, and only mild local skin reactions were noted. During the treatment period, we observed a decrease of peripheral blood leukocytes and CD19+/CD5+ leukemic cells. In one patient, a significant increase of specific cytotoxic T lymphocytes against RHAMM/CD168, a recently characterized leukemia-associated antigen, could be detected after DC vaccination. Taken together, the study demonstrated that DC vaccination in CLL patients is feasible and safe. Immunological and to some extent hematological responses could be noted, justifying further investigation on this immuno-therapeutical approach.</description><subject>Aged</subject><subject>Antigen (leukemia-associated)</subject><subject>Antigen (tumor-associated)</subject><subject>Antigens</subject><subject>Apoptosis</subject><subject>Apoptosis - immunology</subject><subject>Autoimmunity</subject><subject>Biological and medical sciences</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>CD19 antigen</subject><subject>CD5 antigen</subject><subject>Chronic lymphocytic leukemia</subject><subject>Clinical trials</subject><subject>Cytotoxicity</subject><subject>Dendritic cells</subject><subject>Dendritic Cells - immunology</subject><subject>Extracellular Matrix Proteins - immunology</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Hyaluronan Receptors - immunology</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Leukemia</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - immunology</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Leukocytes</subject><subject>Lymphatic leukemia</subject><subject>Lymphocytes</subject><subject>Lymphocytes B</subject><subject>Lymphocytes T</subject><subject>Lysates</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Monocytes</subject><subject>Neoplasm Proteins - immunology</subject><subject>Patients</subject><subject>Peripheral blood</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Solid tumors</subject><subject>Th1 Cells - immunology</subject><subject>Th2 Cells - immunology</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Vaccination</subject><subject>Vaccines</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkk2P1DAMhisEYoeFKzdQBWJvHZI0H-1xWPElrcQFzlWautMMaVKSVKv-Fv4sqWZgAC1COcRxHr-2E2fZU4y2GJXV63DYGpi3hKYDR_eyDaaCF4wxfD_boKoSBa8JvcgehXBAaL3kD7MLzOoaVRxvsu87Y9weLGiVd2A7r2OyFBgT8mk2Abr8Vschj_PofG6WICOEPJlyclN0K9y6TiefDLkex9m6OICX05L3iZpk1GBjOIqA9GYpQpR7yN8Ua5JcDd7ZJGKWcRqcWlbB1NBXGLV8nD3oZSrhyWm_zL68e_v5-kNx8-n9x-vdTaEYr2PBCOlBKk6YELjrSxBCtbJq6x63gtaUCCB1xXvKBa8prnoKTCawRRwLWaLyMrs66k7efZshxGbUYa1OWnBzaHjFMCMl_S-IRVlRjFbFl3-BBzd7m5poCKdMIIFYmagX_6RIAnBJ8FlqLw002vYueqnWvM0OVxUjDNGV2t5BpdWlh1TOQq-T_4-Aq98CBpAmDsGZOWpnw53KyrsQPPTN5PUo_dJg1Kwj2IRDk36sOY1gCnh-6mpuR-jO-GnmEvDqBMigpOm9tEqHMydQLVL6xD07clbG2cMv4GeiH_cM7hw</recordid><startdate>20050901</startdate><enddate>20050901</enddate><creator>HUS, I</creator><creator>ROLINSKI, J</creator><creator>TABARKIEWICZ, J</creator><creator>WOJAS, K</creator><creator>BOJARSKA-JUNAK, A</creator><creator>GREINER, J</creator><creator>GIANNOPOULOS, K</creator><creator>DMOSZYNSKA, A</creator><creator>SCHMITT, M</creator><general>Nature Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20050901</creationdate><title>Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia</title><author>HUS, I ; ROLINSKI, J ; TABARKIEWICZ, J ; WOJAS, K ; BOJARSKA-JUNAK, A ; GREINER, J ; GIANNOPOULOS, K ; DMOSZYNSKA, A ; SCHMITT, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c569t-522feac625771df3e77cba8b9f1b749427e2986f46769418f4e5a1dfb0617a303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Aged</topic><topic>Antigen (leukemia-associated)</topic><topic>Antigen (tumor-associated)</topic><topic>Antigens</topic><topic>Apoptosis</topic><topic>Apoptosis - immunology</topic><topic>Autoimmunity</topic><topic>Biological and medical sciences</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>CD19 antigen</topic><topic>CD5 antigen</topic><topic>Chronic lymphocytic leukemia</topic><topic>Clinical trials</topic><topic>Cytotoxicity</topic><topic>Dendritic cells</topic><topic>Dendritic Cells - immunology</topic><topic>Extracellular Matrix Proteins - immunology</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Hyaluronan Receptors - immunology</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Leukemia</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - immunology</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Leukocytes</topic><topic>Lymphatic leukemia</topic><topic>Lymphocytes</topic><topic>Lymphocytes B</topic><topic>Lymphocytes T</topic><topic>Lysates</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Monocytes</topic><topic>Neoplasm Proteins - immunology</topic><topic>Patients</topic><topic>Peripheral blood</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Solid tumors</topic><topic>Th1 Cells - immunology</topic><topic>Th2 Cells - immunology</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Vaccination</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HUS, I</creatorcontrib><creatorcontrib>ROLINSKI, J</creatorcontrib><creatorcontrib>TABARKIEWICZ, J</creatorcontrib><creatorcontrib>WOJAS, K</creatorcontrib><creatorcontrib>BOJARSKA-JUNAK, A</creatorcontrib><creatorcontrib>GREINER, J</creatorcontrib><creatorcontrib>GIANNOPOULOS, K</creatorcontrib><creatorcontrib>DMOSZYNSKA, A</creatorcontrib><creatorcontrib>SCHMITT, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HUS, I</au><au>ROLINSKI, J</au><au>TABARKIEWICZ, J</au><au>WOJAS, K</au><au>BOJARSKA-JUNAK, A</au><au>GREINER, J</au><au>GIANNOPOULOS, K</au><au>DMOSZYNSKA, A</au><au>SCHMITT, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia</atitle><jtitle>Leukemia</jtitle><addtitle>Leukemia</addtitle><date>2005-09-01</date><risdate>2005</risdate><volume>19</volume><issue>9</issue><spage>1621</spage><epage>1627</epage><pages>1621-1627</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><coden>LEUKED</coden><abstract>Recently, immunotherapies with allogeneic dendritic cells (DCs) pulsed with tumor antigens to generate specific T-cell responses have been tested in clinical trials for patients with solid tumors. This is the first report on a clinical vaccination study with DCs for patients with B-cell chronic lymphocytic leukemia (B-CLL). The potential of allogeneic DCs pulsed ex vivo with tumor cell lysates or apoptotic bodies to stimulate antitumor immunity in patients with B-CLL in early stages was evaluated. Monocyte-derived DCs were obtained from unrelated healthy donors. Nine patients (clinical stage 0 and 1 according to Rai) were vaccinated five times with a mean number of 32 x 10(6) stimulated DCs administered intradermally once every 2-3 weeks. No signs of autoimmunity were detected, and only mild local skin reactions were noted. During the treatment period, we observed a decrease of peripheral blood leukocytes and CD19+/CD5+ leukemic cells. In one patient, a significant increase of specific cytotoxic T lymphocytes against RHAMM/CD168, a recently characterized leukemia-associated antigen, could be detected after DC vaccination. Taken together, the study demonstrated that DC vaccination in CLL patients is feasible and safe. Immunological and to some extent hematological responses could be noted, justifying further investigation on this immuno-therapeutical approach.</abstract><cop>London</cop><pub>Nature Publishing</pub><pmid>15990861</pmid><doi>10.1038/sj.leu.2403860</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-6924 |
| ispartof | Leukemia, 2005-09, Vol.19 (9), p.1621-1627 |
| issn | 0887-6924 1476-5551 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68515234 |
| source | MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Aged Antigen (leukemia-associated) Antigen (tumor-associated) Antigens Apoptosis Apoptosis - immunology Autoimmunity Biological and medical sciences Cancer Vaccines - therapeutic use CD19 antigen CD5 antigen Chronic lymphocytic leukemia Clinical trials Cytotoxicity Dendritic cells Dendritic Cells - immunology Extracellular Matrix Proteins - immunology Female Hematologic and hematopoietic diseases Humans Hyaluronan Receptors - immunology Immunology Immunotherapy Immunotherapy - methods Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - immunology Leukemia, Lymphocytic, Chronic, B-Cell - therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Leukocytes Lymphatic leukemia Lymphocytes Lymphocytes B Lymphocytes T Lysates Male Medical sciences Middle Aged Monocytes Neoplasm Proteins - immunology Patients Peripheral blood Reverse Transcriptase Polymerase Chain Reaction Solid tumors Th1 Cells - immunology Th2 Cells - immunology Treatment Outcome Tumors Vaccination Vaccines |
| title | Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T08%3A55%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Allogeneic%20dendritic%20cells%20pulsed%20with%20tumor%20lysates%20or%20apoptotic%20bodies%20as%20immunotherapy%20for%20patients%20with%20early-stage%20B-cell%20chronic%20lymphocytic%20leukemia&rft.jtitle=Leukemia&rft.au=HUS,%20I&rft.date=2005-09-01&rft.volume=19&rft.issue=9&rft.spage=1621&rft.epage=1627&rft.pages=1621-1627&rft.issn=0887-6924&rft.eissn=1476-5551&rft.coden=LEUKED&rft_id=info:doi/10.1038/sj.leu.2403860&rft_dat=%3Cgale_proqu%3EA188525041%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220531321&rft_id=info:pmid/15990861&rft_galeid=A188525041&rfr_iscdi=true |